Our Insights R&D Insights Anthony Iannacci 3/4/26 R&D Insights Anthony Iannacci 3/4/26 The Problem with Primary Market Research Read More R&D Insights Anthony Iannacci 2/10/26 R&D Insights Anthony Iannacci 2/10/26 Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D Read More R&D Insights Anthony Iannacci 1/27/26 R&D Insights Anthony Iannacci 1/27/26 Finding the Best R&D Opportunities Read More R&D Insights Anthony Iannacci 12/29/25 R&D Insights Anthony Iannacci 12/29/25 Measuring Risk in R&D Read More Oncology, R&D Insights Anthony Iannacci 11/11/25 Oncology, R&D Insights Anthony Iannacci 11/11/25 How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC Read More Oncology, R&D Insights Anthony Iannacci 10/30/25 Oncology, R&D Insights Anthony Iannacci 10/30/25 What indications should we focus on? Read More Oncology, R&D Insights Anthony Iannacci 8/26/20 Oncology, R&D Insights Anthony Iannacci 8/26/20 Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study Read More Oncology, R&D Insights Anthony Iannacci 4/2/20 Oncology, R&D Insights Anthony Iannacci 4/2/20 Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda Read More Oncology, R&D Insights Anthony Iannacci 6/5/19 Oncology, R&D Insights Anthony Iannacci 6/5/19 How to Price an Oncology Drug Read More
R&D Insights Anthony Iannacci 3/4/26 R&D Insights Anthony Iannacci 3/4/26 The Problem with Primary Market Research Read More
R&D Insights Anthony Iannacci 2/10/26 R&D Insights Anthony Iannacci 2/10/26 Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D Read More
R&D Insights Anthony Iannacci 1/27/26 R&D Insights Anthony Iannacci 1/27/26 Finding the Best R&D Opportunities Read More
R&D Insights Anthony Iannacci 12/29/25 R&D Insights Anthony Iannacci 12/29/25 Measuring Risk in R&D Read More
Oncology, R&D Insights Anthony Iannacci 11/11/25 Oncology, R&D Insights Anthony Iannacci 11/11/25 How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC Read More
Oncology, R&D Insights Anthony Iannacci 10/30/25 Oncology, R&D Insights Anthony Iannacci 10/30/25 What indications should we focus on? Read More
Oncology, R&D Insights Anthony Iannacci 8/26/20 Oncology, R&D Insights Anthony Iannacci 8/26/20 Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study Read More
Oncology, R&D Insights Anthony Iannacci 4/2/20 Oncology, R&D Insights Anthony Iannacci 4/2/20 Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda Read More
Oncology, R&D Insights Anthony Iannacci 6/5/19 Oncology, R&D Insights Anthony Iannacci 6/5/19 How to Price an Oncology Drug Read More
